吉非替尼治疗晚期非小细胞肺癌临床疗效研究.docVIP

吉非替尼治疗晚期非小细胞肺癌临床疗效研究[摘要] 目的:观察吉非替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:15例晚期NSCLC患者口服吉非替尼250 mg/d,直到疾病进展或不可耐受的毒副反应停药。结果:本组15例晚期NSCLC患者经治疗后,无CR病例,6例PR(40.0%),5例SD(33.3%),4例PD(26.7%)。总的疾病控制率(CR+PR+SD)为73.3%。全组15例病例中,8例(53.3%)在服药1周后出现Ⅰ/Ⅱ度皮疹。2例(13.3%)发生Ⅰ、Ⅱ度腹泻,1例(6.7%)发生Ⅲ度腹泻;1例(6.7%)出现Ⅱ度谷丙转氨酶(AI)升高。15例患者未见肺纤维化,亦未见心、肝、肾功能损害等毒副作用。结论:口服吉非替尼单药对于经放化疗治疗失败的晚期非小细胞肺癌,是一种有效且具有良好耐受性的治疗方案。 [关键词] 吉非替尼;晚期非小细胞肺癌;化疗;毒性作用;耐受性 [中图分类号] R734.2[文献标识码]A [文章编号]1673-7210(2009)08(b)-035-02 Clinical efficacy analysis of Gefitinib in the treatment of non-small cell lung cancer WANG Cunliang (Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou450052, China) [Abstract] Objective: To observe the clinical efficacy of Gefitinib in the treatment of advanced non-small cell lung cancer(NSCLC). Methods: 15 cases of advanced NSCLC patients with oral Gefitinib 250 mg/day until disease progression or non-tolerance drug toxicity occured. Results: After treatment, no CR cases, six cases of PR(40.0%), 5 cases of SD(33.3%),4 cases of PD(26.7%). The overall disease control rate (CR+PR+SD) was 73.3%. Among all 15 cases, rash of I/Ⅱ degree occured in8 cases(53.3%) one week after the medication, Ⅰ/Ⅱ degree severe diarrhea occurred in 2 cases(13.3%), Ⅲ degrees diarrhea occurred in one cases(6.7%);Ⅱ degree Gubing transaminase(AI) increased in 1 cases(6.7%).NO pulmonary fibrosis occurred,no heart, liver, renal dysfunction and other side effects. Conclusion: Oral Gefitinib mono-therapy is effective and has good tolerability in the treatment of NSCLC patients for which the chemicotherapy failed. [Key words] Gefitinib; Advanced non-small cell lung cancer; Chemotherapy; Toxicity; Tolerance 非小细胞肺癌(non-small cell lung cancer,NSCLC)是常见的恶性肿瘤。吉非替尼是一种具有高度选择性的、口服的表皮生长因子受体酪氨酸激酶拮抗剂,它通过阻断肿瘤细胞生存、增殖中的某些信号转导通路而发挥作用,是一种新型的靶向治疗药物,被用于晚期NSCLC的二线或三线治疗。我院肿瘤科2001年12月～2004年2月,共应用吉非替尼治疗15例晚期NSCLC,取得较好疗效,现报道如下: 1 资料与方法 1.1临床资料 选择我院2001年12月～2004年2月经病理组织学或细胞学确诊为晚期NSCLC患者15例,其中,男11例,女4例,年龄41